ATIC Brings Together Researchers and Community to Discuss Type 1 Diabetes Immunotherapy

The Australasian Type 1 Diabetes Immunotherapy Collaborative held its first town hall to connect patients, families, and clinicians around emerging immunotherapy approaches. The event highlighted the growing focus on immune-based treatments in the region.

cure researchbeta cellsadvancements

Key takeaways

ATIC launched its first public town hall forum to build community awareness of immunotherapy research
The collaborative brings together researchers and clinicians from across Australia to work on Type 1 diabetes immunotherapy
Town halls create a space for patients and families to ask questions directly to experts about emerging treatments
Immunotherapy represents one approach being studied to address the immune system's role in Type 1 diabetes

What is ATIC?

The Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC) is a research initiative connecting researchers and clinicians across Australia focused on immunotherapy approaches to Type 1 diabetes. In February 2023, ATIC held its first public town hall forum, bringing together experts and community members to discuss this work.

Immunotherapy and Type 1 Diabetes

Immunotherapy refers to treatments designed to work with or modify the immune system. In Type 1 diabetes, researchers are exploring how immunotherapy might address the underlying immune process that damages insulin-producing cells. ATIC's focus on immunotherapy represents one avenue of investigation into potential future treatments.

Community Engagement Through Town Halls

The inaugural ATIC town hall forum created an opportunity for patients, parents, caregivers, and community members to connect directly with researchers and clinicians. These events allow people living with or affected by Type 1 diabetes to ask questions about emerging research and understand clinical trials being conducted in their region.

Moving Forward

By hosting community forums, ATIC is working to build awareness and understanding of immunotherapy research in the Australasian region. These conversations help bridge the gap between laboratory discoveries and the people most affected by Type 1 diabetes.

Evidence label

Origin: YouTube / SVIMR St Vincent's Institute of Medical Research (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.